Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002930 · ClinicalTrials.gov registry record · Phase 2

PET Scan in Patients With Lung and Esophageal Cancers That May Be Removed by Surgery

A Phase 2 study of Lung Cancer and Esophageal Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

Completed
Registry status
Phase 2
Development phase
75
Enrollment target
1
Study location

NCT00002930: Completed Phase 2 study of Lung Cancer and Esophageal Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

NCT00002930 is a Phase 2 study of Lung Cancer and Esophageal Cancer that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 75 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002930, a Phase 2 study of Lung Cancer and Esophageal Cancer, has completed, sponsored by Memorial Sloan Kettering Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
75 participants
Enrollment target
1
Study location

Study Summary

RATIONALE: Imaging procedures, such as fludeoxyglucose F 18 positron emission tomography (PET) scans, may improve the ability to detect lung and esophageal cancer or their recurrence. PURPOSE: Phase II/III trial to study the effectiveness of fludeoxyglucose F 18 PET scans in measuring response to induction chemotherapy in patients with esophageal and lung cancer that may be removed by surgery.

Interventions

  • RADIATION fludeoxyglucose F 18
  • PROCEDURE positron emission tomography

Study Locations (1)

New York

  • Memorial Sloan-Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 1996-12
Phase Phase 2
Memorial Sloan Kettering Cancer Center

1,884 total trials

What the finished NCT00002930 record still lists

NCT00002930 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (92% lower).

The record links to 2 conditions, with Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which fludeoxyglucose F 18 is the first listed.

NCT00002930 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT00002930 about?

NCT00002930 is a clinical study titled "PET Scan in Patients With Lung and Esophageal Cancers That May Be Removed by Surgery". RATIONALE: Imaging procedures, such as fludeoxyglucose F 18 positron emission tomography (PET) scans, may improve the ability to detect lung and esophageal cancer or their recurrence. PURPOSE: Phase II/III trial to study the effectiveness of fludeoxyglucose F 18 PET scans in measuring response to i...

What is the current status of trial NCT00002930?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 1996-12.

What conditions does trial NCT00002930 study?

This clinical trial studies the following conditions: Lung Cancer, Esophageal Cancer.

What interventions are being tested in trial NCT00002930?

The interventions under investigation include: fludeoxyglucose F 18 (RADIATION), positron emission tomography (PROCEDURE).

Who is sponsoring clinical trial NCT00002930?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002930 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00002930's enrollment target sits among peer trials

75 215th of 409 higher than 191 of 409 other Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01535430 · 75 participants

    Assessment of Eloquent Function in Brain Tumor Patients

  • NCT01542879 · 75 participants · Phase 1

    Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer

  • NCT02232191 · 75 participants · Phase 2

    Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients

  • NCT02754544 · 75 participants · NA

    Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00002930, the US trial registry maintained by the National Library of Medicine. NCT00002930 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.